The activation of adenosine monophosphate-activated protein kinase in rat hippocampus contributes to the rapid antidepressant effect of ketamine

Behavioural Brain Research

Volumn 253, Issue , 2013, Pages 305-309

  Xu, Shi X ^a   Zhou, Zhi Q ^a   Li, Xiao M ^a   Ji, Mu H ^a   Zhang, Guang F ^a   Yang, Jian J ^a  

^a NANJING UNIVERSITY   (China)

Author keywords

Adenosine monophosphate activated protein kinase; Depression; Hippocampus; Ketamine; Rat

Indexed keywords

5 AMINO 4 IMIDAZOLECARBOXAMIDE RIBOSIDE; BRAIN DERIVED NEUROTROPHIC FACTOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; KETAMINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIDEPRESSANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DEPRESSION; DOWN REGULATION; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME PHOSPHORYLATION; FORCED SWIMMING TEST; HIPPOCAMPUS; IMMOBILIZATION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; UPREGULATION; WESTERN BLOTTING;

ADENOSINE MONOPHOSPHATE-ACTIVATED PROTEIN KINASE; DEPRESSION; HIPPOCAMPUS; KETAMINE; RAT;

AMINOIMIDAZOLE CARBOXAMIDE; AMP-ACTIVATED PROTEIN KINASES; ANIMALS; ANTIDEPRESSIVE AGENTS; BLOTTING, WESTERN; BRAIN-DERIVED NEUROTROPHIC FACTOR; ENZYME ACTIVATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; EXCITATORY AMINO ACID ANTAGONISTS; HIPPOCAMPUS; HYPOGLYCEMIC AGENTS; KETAMINE; MALE; MOTOR ACTIVITY; RATS; RATS, WISTAR; RIBONUCLEOTIDES; SWIMMING;

EID: 84882752632     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2013.07.032     Document Type: Article

References (43)

1. Baune B.T., Adrian I., Jacobi F. Medical disorders affect health outcome and general functioning depending on comorbid major depression in the general population. Journal of Psychosomatic Research 2007, 62:109-118.
2. Kessler R.C., Akiskal H.S., Ames M., Birnbaum H., Greenberg P., Hirschfeld R.M., et al. Prevalence and effects of mood disorders on work performance in a nationally representative sample of U.S. workers. American Journal of Psychiatry 2006, 163:1561-1568.
3. Hashimoto K. The role of glutamate on the action of antidepressants. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2011, 35:1558-1568.
4. Thase M.E., Haight B.R., Richard N., Rockett C.B., Mitton M., Modell J.G., et al. Remission rates following antidepressant therapy with bupropion or selective serotonin reuptake inhibitors: a meta-analysis of original data from 7 randomized controlled trials. Journal of Clinical Psychiatry 2005, 66:974-981.
5. Trivedi M.H., Rush A.J., Wisniewski S.R., Nierenberg A.A., Warden D., Ritz L., et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. American Journal of Psychiatry 2006, 163:28-40.
6. Judd L.L., Akiskal H.S., Schettler P.J., Endicott J., Maser J., Solomon D.A., et al. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Archives of General Psychiatry 2002, 59:530-537.
7. Zarate C.A., Singh J.B., Carlson P.J., Brutsche N.E., Ameli R., Luckenbaugh D.A., et al. A randomized trial of an N-methyl-d-aspartate antagonist in treatment-resistant major depression. Archives of General Psychiatry 2006, 63:856-864.
8. Diazgranados N., Ibrahim L., Brutsche N.E., Newberg A., Kronstein P., Khalife S., et al. A randomized add-on trial of an N-methyl-d-aspartate antagonist in treatment-resistant bipolar depression. Archives of General Psychiatry 2010, 67:793-802.
9. Thangathurai D., Roby J., Roffey P. Treatment of resistant depression in patients with cancer with low doses of ketamine and desipramine. Journal of Palliative Medicine 2010, 13:235.
10. Garcia L.S., Comima C.M., Valvassoria S.S., Réus G.Z., Barbosa L.M., Andreazza A.C., et al. Acute administration of ketamine induces antidepressant-like effects in the forced swimming test and increases BDNF levels in the rat hippocampus. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2008, 32:140-144.
11. Autry A.E., Adachi M., Nosyreva E., Na E.S., Los M.F., Cheng P.F., et al. NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses. Nature 2011, 475:91-95.
12. Li N., Liu R.J., Dwyer J.M., Banasr M., Lee B., Son H., et al. Glutamate n-methyl-d-aspartate receptor antagonists rapidly reverse behavioral and synaptic deficits caused by chronic stress exposure. Biological Psychiatry 2011, 69:754-761.
13. Chen B., Dowlatshahi D., MacQueen G.M., Wang J.F., Young L.T. Increased hippocampal BDNF immunoreactivity in subjects treated with antidepressant medication. Biological Psychiatry 2001, 50:260-265.
14. Shimizu E., Hashimoto K., Olamura N., Koike K., Komatsu N., Kumakiri C., et al. Alterations of serum levels of brain-derived neurotrophic factor (BDNF) in depressed patients with or without antidepressants. Biological Psychiatry 2003, 54:70-75.
15. Li N., Lee B., Liu R.J., Banasr M., Dwyer J.M., Iwata M., et al. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 2010, 329:959-964.
16. Spasic' M.R., Callaerts P., Norga K.K. AMP-activated protein kinase (AMPK) molecular crossroad for metabolic control and survival of neurons. Neuroscientist 2009, 15:309-316.
17. Culmsee C., Monnig J., Kemp B.E., Mattson M.P. AMP-activated protein kinase is highly expressed in neurons in the developing rat brain and promotes neuronal survival following glucose deprivation. Journal of Molecular Neuroscience 2001, 17:45-58.
18. Gadalla A.E., Pearson T., Currie A.J., Dale N., Hawley S.A., Sheehan M., et al. AICA riboside both activates AMP-activated protein kinase and competes with adenosine for the nucleoside transporter in the CA1 region of the rat hippocampus. Journal of Neurochemistry 2004, 88:1272-1282.
19. McCullough L.D., Zeng Z., Li H., Landree L.E., McFadden J., Ronnett G.V. Pharmacological inhibition of AMP-activated protein kinase provides neuroprotection in stroke. Journal of Biological Chemistry 2005, 280:20493-20502.
20. Yoon H., Oh Y.T., Lee J.Y., Baik H.H., Kim S.S., Choe W., et al. Activation of AMP-activated protein kinase by kainic acid mediates brain-derived neurotrophic factor expression through a NF-kappaB dependent mechanism in C6 glioma cells. Biochemical and Biophysical Research Communications 2008, 371:495-500.
21. Hardie D.G. AMPK and raptor: matching cell growth to energy supply. Molecular Cell 2008, 30:214-226.
22. Krishnan V., Nestler E.J. Animal models of depression: molecular perspectives. Current Topics in Behavioral Neurosciences 2011, 7:121-147.
23. Cryan J.F., Mombereau C., Vassout A. The tail suspension test as a model for assessing antidepressant activity: review of pharmacological and genetic studies in mice. Neuroscience and Biobehavioral Reviews 2005, 29:571-625.
24. Lucki I., Dalvi A., Mayorga A.J. Sensitivity to the effects of pharmacologically selective antidepressants in different strains of mice. Psychopharmacology 2001, 155:315-322.
25. Lucki I. The forced swimming test as a model for core and component behavioral e-ects of antidepressant drugs. Behavioural Pharmacology 1997, 8:523-532.
26. Tizabi Y., Bhatti B.H., Manaye K.F., Das J.R., Akinfiresoye L. Antidepressant-like effects of low ketamine dose is associated with increased hippocampal AMPA/NMDA receptor density ratio in female Wistar-Kyoto rats. Neuroscience 2012, 213:72-80.
27. Tizabi Y., Hauser S.R., Tyler K.Y., Getachew B., Madani R., Sharma Y., et al. Effects of nicotine on depressive-like behavior and hippocampal volume of female WKY rats. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2009, 34:62-69.
28. Hauser S.R., Getachew B., Taylor R.E., Tizabi Y. Alcohol induced depressive-like behavior is associated with a reduction in central BDNF. Pharmacology Biochemistry and Behavior 2011, 100:253-258.
29. Baur J.A., Pearson K.J., Price N.L., Jamieson H.A., Lerin C., Kalra A., et al. Resveratrol improve health and survival of mice on a high-calorie diet. Nature 2006, 444:337-342.
30. Altomare D.A., Wang H.Q., Skele K.L., De Rienzo A., Klein-Szanto A.J., Godwin A.K., et al. AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth. Oncogene 2004, 23:5853-5857.
31. Zhang G.F., Wang N., Shi J.Y., Xu S.X., Li X.M., Ji M.H., et al. Inhibition of the l-arginine-nitric oxide pathway mediates the antidepressant effects of ketamine in rats in the forced swimming test. Pharmacology Biochemistry and Behavior 2013, 110C:8-12.
32. Ruderman N.B., Xu X.J., Nelson L., Cacicedo J.M., Saha A.K., Ido Y. AMPK and SIRT1: a long-standing partnership?. American Journal of Physiology - Endocrinology and Metabolism 2010, 298:E751-E760.
33. Fanselow M.S., Dong H.W. Are the dorsal and ventral hippocampus functionally distinct structures. Neuron 2010, 65:7-19.
34. Bonne O., Vythilingam M., Inagaki M., Wood S., Neumeister A., Nugent A.C., et al. Reduced posterior hippocampal volume in posttraumatic stress disorder. Journal of Clinical Psychiatry 2008, 69:1087-1091.
35. Frey B.N., Andreazza A.C., Nery F.G., Martins M.R., Quevedo J., Soares J.C., et al. The role of hippocampus in the pathophysiology of bipolar disorder. Behavioural Pharmacology 2007, 18:419-430.
36. Anderson M.F., Aberg M.A.I., Nilsson M., Eriksson P.S. Insulin-like growth factor-I and neurogenesis in the adult mammalian brain. Developmental Brain Research 2002, 134:115-122.
37. Dechant G., Neumann H. Neurotrophins. Advances in Experimental Biology 2002, 513:303-334.
38. Kempermann G., Kronenberg G. Depressed new neurons - adult hippocampal neurogenesis and a cellular plasticity hypothesis of major depression. Biological Psychiatry 2003, 54:499-503.
39. Santarelli L., Saxe M., Gross C., Surget A., Battaglia F., Dulawa S., et al. Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science 2003, 301:805-809.
40. Shirayama Y., Chen A.C., Nakagawa S., Russell D.S., Duman R.S. Brain-derived neurotrophic factor produces antidepressant effects in behavioral models of depression. Journal of Neuroscience 2002, 22:3251-3261.
41. Moga D.E., Calhoun M.E., Chowdhury A., Worley P., Morrison J.H., Shapiro M.L. Activity-regulated cytoskeletal-associated protein is localized to recently activated excitatory synapses. Neuroscience 2004, 125:7-11.
42. Tan A., Moratalla R., Lyford G.L., Worley P., Graybiel A.M. The activity-regulated cytoskeletal-associated protein arc is expressed in different striosome-matrix patterns following exposure to amphetamine and cocaine. Journal of Neurochemistry 2000, 74:2074-2078.
43. Yasuda M., Fukuchi M., Tabuchi A., Kawahara M., Tsuneki H., Azuma Y., et al. Robust stimulation of TrkB induces delayed increases in BDNF and Arc mRNA expressions in cultured rat cortical neurons via distinct mechanisms. Journal of Neurochemistry 2007, 103:626-636.